Isto Biologics | Top Orthopedic Solutions Company 2023

MedTech Outlook Magazine

Isto Biologics
A New Frontier in Bone Regeneration and Cell-Based Therapies

Brian Barnes, PhD, President & Don Brown, CEO & Nathan Taylor, Sr. VP Sales & Marketing, Isto BiologicsBrian Barnes, PhD, President & Don Brown, CEO & Nathan Taylor, Sr. VP Sales & Marketing
Orthopedics has made tremendous advances in the last two decades with pioneering techniques and state-of-theart technologies to enhance patient care and improve outcomes. However, even with cutting-edge resources such as advanced imaging technologies, robotics, hardware, and minimally invasive surgical techniques, orthopedic surgeons may still require alternative treatment options.

Orthobiologics—a branch of regenerative medicine—has the potential to significantly improve patient outcomes by promoting healing and accelerating recovery times.

Isto Biologics is at the forefront of orthobiologic innovations, leading the development of regenerative technologies and innovative solutions to help patients heal faster.

From its roots in autologous therapies, the firm has evolved into a pure-play biologics company, expanding its focus from cell signaling to the critical scaffolding required to support it. While tissue repair still remains at the core of its business model, the firm adapted to this shift in the bone repair space by utilizing allograft donor tissue as the scaffold source.

“Remaining agnostic to the fixation component of bone repair and focusing on cell signaling and scaffolding resonates with our mission, particularly as surgeons become more articulate in the value of the cell source and cell signaling,” says Don Brown, CEO of Isto Biologics.

Their commitment to delivering market-leading solutions to surgeons remains unwavering, as demonstrated in Isto’s impressive portfolio of cutting-edge products. Through an evolving lineup of autologous therapies, allograft tissue products, and biosynthetic bone grafts, Isto is breaking new ground in tipto- tail spinal fusions and foot-ankle surgery.
At the forefront of their offerings is the Magellan® line, which enables surgeons to harness the therapeutic potential of cellbased therapies like PRP and cBMA to promote tissue repair and bone formation around the surgical site. Isto also offers innovative bone graft solutions through their Influx™ and InQu® lines, both of which promote new tissue growth to treat injuries caused by trauma, overuse, or prior surgical procedures.

The firm recently launched Fibrant™, a line of functional allograft constructs made from 100% cortical fibers. Due to the proprietary nature of Fibrant’s longer and stronger fiber technology, Isto is able to offer several types of bone grafts for procedures that have had limited solutions in the past. The Fibrant line includes five items, two of which stand out due to their novel characteristics and healing potential. The Fibrant Anchor is a 100% cortical allograft fixation sleeve that provides ultimate strength and stability for pedicle screws. The Fibrant Pak is a cortical fiber pouch that sets a new standard for graft delivery and containment, given the pouch itself is 100% graft.

We are continuously looking to propel the field of orthobiologics forward and pride ourselves on not only providing great products, but also being a resource for surgeons,” says Brian Barnes, President of Isto Biologics

As Isto stands committed to pioneering advancements both organically and through collaborations, the firm is gearing up to unveil the latest development in its PRP and concentrated marrow technology this summer. This new innovation, known as Precise, will enable greater flexibility for different treatments by allowing the removal of specific cell types without compromising platelet concentrations.

Isto Biologics recognizes the wealth of possibilities that lie ahead and remains committed to its devotion to helping patients heal faster. “We are continuously looking to propel the field of orthobiologics forward and pride ourselves on not only providing great products, but also being a resource for surgeons,” says Brian Barnes, president of Isto Biologics.

Top 10 Orthopedic Solutions Companies - 2023

Company
Isto Biologics

Management
Brian Barnes, PhD, President & Don Brown, CEO & Nathan Taylor, Sr. VP Sales & Marketing

Description
Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. Isto is equipped to offer a range of customizable options to surgeons of varying specialties.

Isto Biologics News

Advanced Biologics Elevates Biologic Innovations Through Merger with Isto Biologics.

CARLSBAD - announced today their successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.
The merger will seamlessly integrate Advanced Biologics' proprietary products into Isto's esteemed and growing portfolio of allografts found within their Influx™ line.
"We are thrilled for our entire Advanced Biologics/Biologica team to join forces with Isto Biologics, said Amit Govil, President of Advanced Biologics. "This merger brings together the clinical, commercial, and research-driven expertise of both companies' and a shared commitment to help patients heal faster."
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto's Integrative Bone Matrix, SPARC™. SPARC is a novel inductive bone matrix that stemmed from Advanced Biologics' proprietary tissue processing method used in their well-known allograft, OsseoGen®. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
The integration of Advanced Biologics' product commercialization initiatives into Isto's growing allograft portfolio provides a unique opportunity to help patients heal faster and enable both customer bases to benefit from the broadened product set.
"Over the past four years, our collaboration with Advanced Biologics has been impressive," said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners (TSCP). "Investing in Advanced Biologics and embarking on this strategic combination amplifies both Isto's and Advanced Biologics' comprehensive biologics portfolios, paving a path forward for continued growth and patient healing."
"With this merger, our combined team is now elevated with greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market," said Don Brown, CEO of Isto Biologics.